The European Society of Cardiology have just released 2019 guidelines relating to diabetes, pre-diabetes and cardiovascular diseases. There have been a range of changes relative to the previous guidelines released in 2013. Pharmacological highlights include:

  • More individualised guidance about lowering BP, in particular for older people
  • More assertive guidelines for lowering LDL-cholesterol for people with cardiovascular risk
  • A suggestion to consider low dose aspirin for people with diabetes and high CV risk, provided there are not significant contraindications
  • A suggestion that DOAC anticoagulants should be considered preferentially relative to warfarin for those with AF

Read the updated guidelines here